Region — US. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Explore  /  Naringenin
Research reference — not for sale

Naringenin

B
lead outcome
Topical: anti-oxidative barrier protection
grades vary by outcome ↓
Small molecule (non-peptide)
also called — 4′,5,7-trihydroxyflavanone · flavanone · grapefruit polyphenol · biotech-fermented naringenin (Debut / Deinde) · INCI: Naringenin
skin appearance (cosmetic)antioxidantanti-inflammaging (mechanism-level)barrier support

Naringenin is a lawful cosmetic ingredient globally. Vallydia does not currently sell a naringenin product — the biotech-fermented form is exclusively formulated into the Deinde brand by Debut Biotech, and plant- extracted forms of varying purity are used by other brands. This registry entry provides independent evidence-grading as a reference; the reference science below spans both cell/animal mechanism studies and one in-house brand clinical trial.

In brief

Naringenin is a flavanone polyphenol naturally present in citrus fruits (concentrated in grapefruit peel). Independent laboratory research (2016–2024) consistently shows it has meaningful biological activity on skin cells: anti-inflammatory, anti-oxidative, MMP-suppressing, UV- protective — and, uniquely among four common polyphenols in a 2024 comparison, superior anti-lipoperoxidation in stratum corneum. However, every one of these independent studies is either in-vitro (cells, reconstructed skin models) or on animals. The only human clinical trial is an in-house study by Debut Biotech / Deinde (n=30, 8 weeks, 0.45% naringenin), which is a promising signal but not independent proof of visible anti-aging effect. The claim "15× more effective than niacinamide" is a cell-culture single-biomarker comparison, not a head-to-head clinical trial. Naringenin is a plausible barrier-protective, gentle anti-oxidative ingredient — appropriate for sensitive and perimenopausal skin — but the strong marketing framing outruns the current independent evidence base.

Legal standing, by region
International
Lawful cosmetic ingredient

Topical Naringenin is a lawful cosmetic ingredient in the EU (Regulation (EC) 1223/2009), UK, US, and Asia. CosIng-listed. Biotech- fermented naringenin (produced by Debut Biotech and used exclusively in the Deinde brand) is chemically identical to plant-extracted naringenin and follows the same regulatory pathway. Not restricted.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Topical: anti-oxidative barrier protection
In vitro / ex vivo skin model; not a visible-outcome human RCT; independent replication with clinical endpoints still lacking
Ruscinc et al. 2024 (Frontiers in Chemistry) — comparative study of 4 polyphenols in 0.1% gels; naringenin the only one showing significant anti-lipoperoxidation in stratum corneum (others were pro-oxidant under UV stress) · Reduction of UV-induced lipid peroxidation in stratum corneum; superior to chlorogenic acid, apigenin, kaempferol
B
Topical: MMP-1 suppression / anti-photoaging (mechanism)
All independent evidence is in-vitro (cells, reconstructed epidermis) or animal (mice); no independent human RCT with visible endpoints
Yin 2016 (J Cell Mol Med) — naringenin binds ERK2 and suppresses UVB-induced MMP-1 in cells and mice; Martinez 2016 (PLOS ONE) — topical naringenin cream reduced UVB-induced skin inflammation and oxidative damage in hairless mice; Martinez 2023 (Cosmetics MDPI) — UVB and pollution protection in human skin cells · Consistent anti-inflammatory, anti-oxidative, MMP-suppressing activity across independent labs
B
Anti-inflammatory (skin senescence / inflammaging mechanism)
In vitro; effect in living skin harder to demonstrate; brand-affiliated claims of "15× more effective than niacinamide" derive from cell-culture single-biomarker comparison at unmatched concentrations — not head-to-head clinical
Kim 2018 (Biomedical Dermatology) — human dermal fibroblasts; naringenin activates SIRT1, blocks NF-κB, reduces MMP expression. Published 6 years before Deinde launch, no brand affiliation. · Reduction of inflammatory cytokines and MMPs in fibroblast cell models
B
Visible anti-aging / inflammaging (finished product)
Small sample size; in-house / brand-run; no independent replication; "% of participants improved" does not report magnitude of change
Deinde in-house RCT — 8 weeks, placebo-controlled, double-blind, n=30, 0.45% naringenin serum; 100% moisture/elasticity, 97% fine-line reduction reported · Improvement in subject-assessed and instrumental endpoints
C
Pigmentation / melanogenesis (in-vitro)
Not translated to clinical endpoints; other polyphenols show similar in-vitro effects that do not translate to visible in vivo results
Martinez 2023 — pigmented reconstructed epidermis; naringenin reduced pigmentation-related gene expression and melanin content · In-vitro pigmentation reduction
C
Safety (topical)
Photostability of the molecule under UV requires appropriate formulation; grapefruit-derived versus biotech-fermented forms are chemically identical
Ruscinc 2024 HET-CAM assay — non-irritating; decades of dietary exposure (citrus consumption); no significant topical safety signals · Well tolerated
Cosmetic claims boundary
✓ Allowed (appearance / feel)
  • for the appearance of calm, healthy-looking skin
  • supports the look of a resilient skin barrier
  • antioxidant
  • helps skin look protected from environmental stress
✕ Not allowed (medicinal)
  • reverses aging
  • interrupts the root cause of skin aging
  • 15 times more effective than niacinamide
  • reduces inflammation
  • anti-inflammatory
  • stops inflammaging
  • inhibits MMP
  • protects collagen (as a stand-alone claim)

The medicinal-sounding science stays in the reference section; product copy speaks only to appearance/feel (Reg 655/2013). Different fields, never merged.

Identity

a flavanone — specifically 4′,5,7-trihydroxyflavanone — a subclass of flavonoid polyphenols. Naturally present in citrus fruits, most concentrated in the peel and pith of grapefruit and other citrus. Bitter taste characteristic (naringin, the glycoside form, is responsible for grapefruit bitterness; naringenin is the aglycone). Also produced by biotech fermentation using engineered microorganisms — Debut Biotech's process yields ~99% pure naringenin used exclusively in their Deinde brand at 0.45% concentration.

Development & history

  • Isolated and characterised as a citrus flavonoid in the mid-20th century.
  • Extensive study since the 1990s as a dietary polyphenol with anti-oxidative, anti-inflammatory, and metabolic activity.
  • Topical skin research began in the 2010s: Martinez 2016 (topical cream in mouse UVB model), Yin 2016 (ERK2/MMP-1 mechanism), Kim 2018 (SIRT1/NF-κB in human fibroblasts) — all published before any consumer brand licensed the ingredient.
  • Debut Biotech developed a biotech-fermented naringenin, obtained patents, and launched it as the flagship active in their DTC brand Deinde in January 2024, positioning it around the concept of "inflammaging" (a 25-year-old immunology term coined by Franceschi in 2000).
  • Ruscinc 2024 (Frontiers in Chemistry) — most rigorous independent comparative study to date — found naringenin uniquely superior among four polyphenols for stratum corneum anti-lipoperoxidation.
  • Consumer awareness rose sharply through 2024–2025; ingredient remains almost exclusively associated with the Deinde brand in the DTC market.

Mechanism (as proposed)

a flavonoid that acts through multiple documented pathways in skin cells. It binds directly to ERK2, blocking UVB-induced MMP-1 expression (mechanism suppressing collagen degradation, per Yin 2016). It activates SIRT1 and blocks NF-κB inflammatory signalling in dermal fibroblasts (mechanism reducing senescence-associated cytokines, per Kim 2018). It shows anti-oxidative activity — uniquely among common cosmetic polyphenols, it protects rather than damages stratum corneum lipids under UV stress (Ruscinc 2024). In pigmented reconstructed epidermis it reduces melanogenesis gene expression (Martinez 2023). The biotech marketing framing translates these mechanisms as "interrupting inflammaging" and "15× more effective than niacinamide" — these translations require caution: the cell-culture and animal evidence is real, but the extrapolation to visible anti-aging results on human faces currently rests on one in-house 30-person clinical study by the brand selling the product.

Sources — 6 cited
01Martinez RM, et al. Topical Formulation Containing Naringenin: Efficacy against Ultraviolet B Irradiation-Induced Skin Inflammation and Oxidative Stress in Mice. PLOS ONE. 2016.
02Yin Y, et al. Naringenin targets ERK2 and suppresses UVB-induced photoaging. J Cell Mol Med. 2016.
03Kim HK, et al. Inhibitory effect of naringenin on LPS-induced skin senescence by SIRT1 regulation in HDFs. Biomedical Dermatology. 2018.
04Martinez RM, et al. Protective Effects of Naringenin against UVB Irradiation and Air Pollution-Induced Skin Aging and Pigmentation. Cosmetics MDPI. 2023; 10(3):88.
05Ruscinc N, et al. Comparative study of four polyphenols (chlorogenic acid, apigenin, kaempferol, naringenin) on stratum corneum lipid peroxidation. Frontiers in Chemistry. 2024.
06Franceschi C, et al. Inflammaging: an evolutionary perspective on immunosenescence. Ann NY Acad Sci. 2000. (context — the concept naringenin marketing is built around)
Review status
Not yet reviewed

A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated 2026-07-07.

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
EctoinB
Small molecule (non-peptide)
GHK-Cu (Copper Tripeptide-1)B
Peptide
Explore by goal
Skin & aesthetic
Vallydia

A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.

Region — United States
ExploreRegisterCategoriesTrust & COAHow we grade
ShopCosmetic peptidesJournal
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.

Naringenin — evidence, uses & status · Vallydia